Pharmacia & Upjohn Company

The Upjohn Co.

Washington University

Magenta Therapeutics, Inc.

Gencia Corporation

Pioneura Corporation

Other

Lycera Corporation

Imago Biosciences, Inc.

Pah P&u LLC

Elan Oharmaceuticals, Inc.

Edigene Biotechnology Inc.

Arthur Glenn Romero

Chiu-Hong Lin

Susanne R Haadsma-Svensson

Michael D Ennis

Peter Laurence Toogood

John Michael McCall

Michael R Barbachyn

Dennis Joseph McNamara

John R Palmer

Per A Carlsson

Alexander Ross Hurd

Hakan V Wikstrom

Bengt R Andersson

Lisa Marie Thomasco

John Alan Tucker

Shaharyar Khan

Karen Rene Romines

Jesse Damsker

Harris A Gelbard

John C Sih

William L Thomas

Gordon L Bundy

John Nicholas Freskos

Varghese John

Gary D Glick

Donna Lee Romero

David Louis Brown

Thomas Daniel Aicher

Yvette M Fobian

Joseph Walter Strohbach

He Zhao

Robert C Gadwood

Valerie Ann Vaillancourt

Jian-Min Fu

Ruth Elizabeth TenBrink

Zhan Wang

Heinrich Josef Schostarez

Suvit Thaisrivongs

Cassandra Celatka

Chad A VanHuis

William H Darlington

Nils P Stjernlof

Debra Ann Sherry

Stig Thomas Elebring

Jeffrey A Leiby

Paul Joseph Dobrowolski

J Craig Ruble

Michael J Holtzman

Kerry Anne Cleek

Zhenfu Han

Bradley D Hewitt

Kjell Anders Svensson

Jiong Jack Chen

Thomas Andrew Runge

Shamus P Keeler

Benjamin J Gerovac

Kangyun Wu

Montford F Piercey

Kjell Anders Ivan Svensson

Chad A Van Huis

Kjell A Svensson

Amy E Tapper

Carl J Kaub

Elisabeth C A Brot

Robert B McCall

Matthew N Mattson

Jeanette Kay Morris

Karin Ann Stein

Jian-Xie Chen

Xuemei Chen

Robert A Lahti

Larry Fang

Xiaoming Liao

Zhihua Li

Olivier Bezencon

Kevin A Goncalves

Yong Zhang

Gary E Martin

Gordan L Bundy

Christina M Roels

James Craig Ruble

Dhara Patel

Thomas Brett

Anand Patel

Yael Alevy

Erik Krogh-Jespersen

Mikael C Herlevsen

Betina Biolatto

Toni Chancellor

Carl Kaub

Michael Robert Barbachyn

Dennis Joseph Mcnamara

John Raymond Palmer

William David Thomas

Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.

Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof

Provided is a tartrate salt of 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine and crystalline forms thereof. Also provided are pharmaceutical compositions comprising a tartrate salt disclosed herein and crystalline forms thereof and a pharmaceutically acceptable excipient, and a method of treating a disease or disorder, such as disease or disorder associated with neuroinflammation, comprising administering to a subject in need thereof, a therapeutically effective amount of an acid addition salt disclosed herein or the pharmaceutical composition of the acid addition salt.

Acid addition salts, compositions, and methods of treating

Provided is an acid addition salt of 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine selected from a tartrate salt, a phosphate salt, and a fumarate salt. Also provided are pharmaceutical compositions comprising an acid addition salt disclosed herein and a pharmaceutically acceptable excipient, and a method of treating a disease or disorder, such as disease or disorder associated with neuroinflammation, comprising administering to a subject in need thereof, a therapeutically effective amount of an acid addition salt disclosed herein or the pharmaceutical composition of the acid addition salt.

Acid addition salts, compositions, and methods of treating thereof

Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.

Methods and processes for the preparation of KDM1A inhibitors

The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.

Aryl hydrocarbon receptor antagonists and uses thereof

The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).

Compositions and methods for treating conditions that affect epidermis

The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR&#x3b3; activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ROR&#x3b3; activity and the treatment of disease

The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each Ris independently hydrogen, alkyl, or a phosphate group; Ra linker; Ris a spacer group; Ris hydrogen, alkyl, aryl, or heterocyclic; or Rand R, or Rand R, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl. 

Modified creatine compounds

Disclosed are methods of identifying, generating and synthesizing compounds that inhibit MAPK13 activity. In various embodiments, compounds, salts thereof and prodrugs thereof of the present teachings can be useful for the treatment of diseases and disorders that involve excess mucus production.

Anti-mucus drugs and uses therefor

The present invention is directed to tricyclic tetrahydroquinoline compounds of formula I, and pharmaceutically acceptable salts thereof wherein the variables R, R, R, R, R, Rand X are as described herein and to pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.

Tricyclic tetrahydroquinoline antibacterial agents

The invention includes tetrahydroquinoline and related compounds of formula I and pharmaceutical compositions thereof, that exhibit useful antibacterial activity again a wide range of human and veterinary pathogens 

Disclosed are compounds of formula: and pharmaceutically acceptable salts and esters thereof, useful in treating and/or preventing Alzheimer's disease and other similar diseases, wherein R, R, R, n and Rare defined herein. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.

Amine 1,2- and 1,3-diol compounds

Growing community of inventors

Chesterfield, MO, United States of America

Arthur Glenn Romero